Paravalvular leak (PVL) is a known complication of surgical and transcatheter valve replacement procedures. Patients most commonly present with congestive heart failure and/or hemolysis, and repeat surgical procedures to correct the PVL carries increased risk with reduced likelihood of success. As a result, percutaneous approaches to PVL closure have been developed, with a considerable emphasis on multimodality imaging for both diagnosis and procedural guidance in the cardiac catheterization laboratory. Large series' of percutaneous PVL closure have been recently published, with encouraging results with respect to both procedural success and clinical outcomes. In this paper, we provide a comprehensive review of imaging and procedural techniques for percutaneous PVL closure and present the data supporting this novel treatment strategy.
Introduction
Each year, approximately 9,000 patients undergo aortic valve replacement (AVR) and 6,000 patients undergo mitral valve replacement (MVR) in the United States [1, 2] . Unfortunately, 1-5 % of patients with an AVR and 2-12 % with an MVR may develop regurgitation between the valve prosthetic and the native cardiac tissue, or paravalvular leak (PVL) [3] [4] [5] . Furthermore, up to 17 % of patients who undergo transcatheter aortic valve replacement (TAVR) may experience moderate or severe PVL, also referred to as paravalvular aortic regurgitation (PAR) [6] . In patients with surgical valve replacement, the use of mechanical valves, severe calcification of the valve anulus, or valve replacement for infectious endocarditis all provide increased risk for the development of PVL post-operatively. With the exception of endocarditis (for which TAVR is not performed), similar factors contribute to PVL in the post-TAVR setting in addition to improper preprocedural valve sizing [7] .
Up to 85 % of patients with symptomatic PVL present with congestive heart failure, and almost 50 % may have hemolysis either in addition to CHF or as the primary presenting complaint [8, 9] . The first-line treatment is medical therapy using afterload-reducing agents and diuretics, as well as erythropoetic agents or transfusion if necessary. For patients with symptoms resistant to these treatments, however, invasive correction of the PVL may be necessary. While reoperation may be an option, redo surgery carries a high recurrence rate of PVL, as the risk factors for its occurrence are likely still present. Furthermore, redo open-heart surgery (OHS) carries a higher risk of morbidity and mortality than the initial procedure [10] .
Given the incidence of PVL and the risks associated with reoperation, interventional cardiologists have developed methods for percutaneous PVL closure [11] . First reported in 1992, the procedure has since been successfully performed, and improved upon, in a number of different centers [12, 13•, 14••, 15••] . In this review, we will provide the evidence behind percutaneous PVL closure techniques, and briefly discuss some of the technical considerations behind this innovative procedure.
Diagnosis
The diagnosis of PVL is suggested by the presentation of CHF or hemolytic anemia in a patient with mechanical or bioprosthetic valve replacement. Blood tests for anemia and serum markers of hemolysis (lactate dehydrogenase (LDH) and haptoglobin) are useful in suggesting the diagnosis. When PVL is suspected, the imaging modality of choice is echocardiography. Transthoracic echocardiography is an important first-line step, as it provides noninvasive information about ventricular function as well as status of the valve. However, especially in the setting of mechanical valve replacement, shielding by the prosthesis may not provide an adequate characterization of the degree or the nature of the leak. Therefore, even if the leakage is considered minimal by TTE, it is important to evaluate more thoroughly using transesophageal echocardiography (TEE) when the diagnosis is suspected on clinical grounds. In some rare situations, it may be unclear whether the leak is intra-or para-valvular by both TTE and TEE. Intracardiac echocardiography (ICE) may be employed to further elucidate the area of regurgitation.
Echocardiographic diagnosis
The use of TTE and TEE are complementary in diagnosing PVL and localizing the defect. It is important to ascertain the true origin of the regurgitant jet, as these leaks are often so eccentric that create very turbulent flow and make proper localization difficult.
Diagnosis of mitral PVL
In order to facilitate communication among interventionalists, surgeons, and imaging specialists, it is important to establish a consistent system for identification of PVL location. The MV is therefore viewed as a "clock face" from the left atrial (LA), or "surgeon's" view, with the 12 o'clock position at the aortic valve. Figure 1A demonstrates the clock face orientation as viewed from the left ventricle (LV). In surgical series, the most common PVL locations were anteromedially (10- As discussed above, TTE may suggest the presence of PVL, but TEE is the mainstay of diagnosis and localization. Determination of PVL location requires an understanding of the relationship of the TEE imaging crystal to the mitral valve (MV) plane. Figure 1B demonstrates the views provided by the TEE probe at the given angulation; movement of the TEE probe cranial or caudal, and anteflexion or retroflexion of the imaging crystal, cuts the valve at planes parallel to dotted lines provided in the figure.
Three-dimensional TEE (3D TEE) can provide an important understanding of the MV, though visualization of a PVL can sometimes be difficult. Conversely, artifact due to echo dropout and shadowing of a mechanical prosthesis may result in echolucent spaces between the valve and the paravalvular space that do not actually exist. The addition of color Doppler can provide important adjunctive information regarding the presence (or absence) of a true paravalvular space (Fig. 2) .
Diagnosis of aortic PVL
The aortic valve (AV) is also viewed as a clock-face, with the 12 o'clock position mirroring that of the MV (Fig. 3A) . Aortic PVL are most commonly encountered at the 7-11 o'clock position (46 %), followed by the 11-3 o'clock position (36 %) [14••] . It is also reasonable to use the relationship of the native coronary cusp to delineate the position of the PVL (i.e. right, left, and noncoronary cusps), a nomenclature that keeps the position of the coronary ostia in mind while pursuing percutaneous PVL closure. Figure 3B demonstrates the orientation of the TEE in short-axis to the aortic valve in a patient with aortic PVL at the 9-10 o'clock position (i.e. at the area of the NCC or interatrial septum). 
Outcomes of percutaneous PVL closure
A number of case reports and small series of percutaneous PVL closure have been published, with encouraging but variable results [13•] . The two largest series, one by Ruiz and colleagues and the other by Sorajja and colleagues, were both published in 2011.
Sorajja and colleages published their short-term outcomes of closure for 141 defects (115 patients, 78 % mitral, 22 % aortic) and long-term outcomes on closure of 154 defects (126 patients) [15••, 16] . Most patients presented with CHF (93 %), but at 3-year follow-up 72 % of those surviving had no or minimal dyspnea. Hemolysis was present among 37 % of patients, and almost 50 % of these patients who survived at 3-years had continued hemolysis, unrelated to degree of residual leak, and only 1 patient experienced worsening hemolysis. Overall procedural success was demonstrated in 77 % of patients, with 8.7 % of patients experiencing a major adverse event at 30 days. Importantly, regurgitation 9 3+ after closure was seen in only 10 %. With respect to safety of the procedure, only one patient required emergent surgery due to valve interference by a device that could not be retrieved percutaneously, and there were no procedural deaths At 3 years, 64 % of patients were alive, and survival was unrelated to the degree of residual regurgitation.
Ruiz and colleagues performed 57 PVL procedures in 43 patients, demonstrating a procedural success of 86 % and a 30-day all-cause mortality rate of 5.4 %; similar surgical series have demonstrated a mortality of 6 % [8, 14••]. Among the group, 10 required a re-do percutaneous procedure, and two required three procedures total, implying both the safety of repeat percutaneous procedures, and the idea that continued valve dehiscence may lead to new or worsening leaks. Another important finding was that although 35 % of patients developed worsened hemolysis, the number of patients requiring regular transfusion or erthyropoetic agents decreased from 56 to 5 %.
Overall, small reports and the above large series have demonstrated the safety and efficacy of percutaneous PVL closure. It is important to remember that the patients undergoing these procedures generally have other significant comorbidities, and represent a high-risk group. Nevertheless, given the significant functional limitations faced by patients with PVL, and the high risks and poor results of reoperation, percutaneous PVL closure presents a promising treatment that is likely to improve with time and innovation.
Procedural imaging
Echocardiography, especially TEE (preferably with 3D capability), is indispensible as an adjunctive imaging modality to fluoroscopy in the cardiac catheterization laboratory. We routinely use TEE to assess device positioning and PVL resolution prior to conclusion of the procedure. However, since we perform most of our percutaneous PVL closure procedures without general anesthesia and intubation, it is important to minimize TEE probe dwell-time for the sake of patient comfort and respiratory concerns. We therefore rely heavily on intracardiac echocardiography (ICE) and the overlay of computed tomography (CT) on the fluoroscopic image for procedural guidance.
Intracardiac echocardiography
We routinely use intracardiac echocardiography (ICE) for puncture of the interatrial septum, as location of the puncture should be specific to the location of the PVL [17] . Furthermore, in patients with a relatively medial leak and a bioprosthetic valve without much shadowing artifact, it may be possible to visualize the PVL well enough to use ICE alone as guidance for closure (Fig. 4) .
CT: Fluoroscopy overlay
In recent years, cardiac CT has become increasingly valued in the planning of transcatheter interventions as a result of its ability to provide a 3D dataset that can be manipulated in countless ways to better understand intracardiac anatomy [18] [19] [20] . The ability to integrate CT-data with fluoroscopic images has been demonstrated by investigators working on structural cardiac procedures, endovascular aortic repair, intracranial intervention, and electroanatomical mapping [21] [22] [23] [24] . After identifying the PVL through an analysis of the TEE and other adjunctive imaging, markings are made on a preprocedural MDCT (Fig. 5A) . A C-arm CT-like image is then obtained (syngo DynaCT Cardiac, Siemens Healthcare, Forcheim, Germany), the image quality of which does not allow a thorough intracardiac analysis; it does, however, establish the position of the patient on the procedure table, and therefore allows a "registration" of the preprocedural CT to the CT acquired in the cath lab. Once this step is completed, the markings made on the preprocedural CT are overlaid onto the real-time fluoroscopic image (Fig. 5B) , which allows guidance of wires and catheters to the location of interest (Fig. 5C) . 
PVL closure techniques
As previously mentioned, there are a number of possible approaches to both mitral and aortic percutaneous PVL closure. Catheters and devices may be delivered via transseptal puncture, direct access to the LV apex, or retrograde via the femoral artery. The choice of access site should be decided on the basis of PVL location, support required for delivery of the bulky closure devices, and presence of other mechanical prostheses that may interfere with wire snaring/externalization. Thorough procedural planning and image analysis is integral to a successful procedure. Furthermore, since we perform all of our PVL closure procedures without general anesthesia or endotracheal intubation, minimizing TEE-probe dwell time is essential for patient comfort. We therefore rely on ICE as well as CT-fluoro overlay for procedural guidance, and place the TEE probe once the device is in place (but prior to release).
Mitral PVL are usually approached using transseptal puncture using femoral venous access (Fig. 6 -use aloairi images) . Once the defect is crossed with a wire, it is usually necessary to externalize the wire to provide more support for the passage of bulky delivery catheters and devices across the leak. This can be accomplished by snaring the wire in the descending aorta and externalizing it via a sheath at the femoral artery, or by placing a small (usually 5-French) sheath in the LV apex for patients with mechanical AV prosthesis. Alternatively, the defect can be approach directly via transapical access (snaring of the wire via a transseptal sheath may or may not be necessary), or retrogradely via arterial access followed by crossing the aortic valve (rarely performed). Once the wire is across the PVL and stabilized, a delivery catheter is passed across the defect and used to deliver the closure device. We Aortic PVL are usually approached via the retrograde arterial route using femoral artery access. Snaring of the wire via transapical sheath may or may not be necessary. Once again, a delivery catheter is advanced across the PVL and a closure device is deployed (Fig. 7) .
As both mitral and aortic PVL can be crescentic in nature, it is important to have appropriate intraprocedural imaging to confirm minimal residual leak at the conclusion of the procedure. If the remaining degree of PVL is considered too substantial, placement of more devices may be necessary (as in Fig. 2C ). For this reason, we prefer to leave a wire across the PVL while deploying closure devices in order to maintain "access" to the defect until confirmation of successful closure (Fig. 6X) .
Conclusions
In patients with prior cardiac valve replacement, clinicians must be vigilant in assessing signs and symptoms or paravalvuar leak, such as CHF and hemolysis. While diagnosis alone does not obligate closure of the PVL, some patients require intervention for symptoms recaltrant to medical therapy. Reoperation in these cases confers substantial risk, and the results are not always durable. Percutaneous PVL closure is therefore an important resource to patients, and in many centers is becoming the first-line therapy for this condition. Further innovation in this field is likely to provide even better efficacy along with improved safety.
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